Meeting
2022 ASCO Gastrointestinal Cancers Symposium
Real-world cost-effectiveness of first-line gemcitabine + nab-paclitaxel versus FOLFIRINOX in patients with advanced pancreatic cancer: A population-based retrospective cohort study in Ontario, Canada.
Authors
Vanessa Arciero
Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada
Vanessa Arciero , Jin Luo , Ambika Parmar , Wei Fang Dai , Jaclyn M. Beca , Michael J. Raphael , Wanrudee Isaranuwatchai , Steven Habbous , Mina Tadrous , Craig Earle , Jim Biagi , Nicole Mittmann , Jessica Arias , Scott Gavura , Kelvin K. Chan
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Patient-Reported Outcomes and Real-World Evidence
DOI
10.1200/JCO.2022.40.4_suppl.529
Abstract #
529
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Gastrointestinal Cancers Symposium
First-line chemotherapy regimens associated with survival in advanced pancreatic cancer: A Mexican single-center, real-world study.
First Author: Marytere Herrera
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Efficacy of the third-line chemotherapy in patients with advanced pancreatic cancer.
First Author: Bomi Kim
Poster
2022 ASCO Gastrointestinal Cancers Symposium
A phase I study of first-line L-glutamine (Gln) with gemcitabine (gem) and nab-paclitaxel (nab-p) in advanced pancreatic cancer (GlutaPanc).
First Author: John Davelaar
Poster
2020 Gastrointestinal Cancers Symposium
First-line drug selection versus sequential treatment in advanced pancreatic cancer: Does it really matter? Multi-institutional Canadian perspective.
First Author: Ivan Barrera